Cobra signs deal with the Naval Medical Research Center of the US Navy to construct and test a vaccine against malaria using Cobra's proprietary Ort-Vac oral vaccine delivery technology
Malaria affects about 300-500 million people per year and is responsible for about 2.7 million deaths annually.
It is a parasitic disease that is transmitted by mosquitoes.
As with tuberculosis, the number one killer ahead of malaria, the emergence of drug resistant strains is a major problem, as is the emergence of insecticide resistant strains of mosquitoes.
Cobra is already in the course of evaluating the Ort-Vac platform in the development of a vaccine against anthrax and plague with UK Defence Science and Technology Laboratory, Porton Down.
Similar technology will be used for this collaboration with the US Navy.
